SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-016706
Filing Date
2024-01-26
Accepted
2024-01-26 16:06:59
Documents
13
Period of Report
2024-01-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d687696d8k.htm   iXBRL 8-K 23474
2 EX-10.1 d687696dex101.htm EX-10.1 4562
  Complete submission text file 0001193125-24-016706.txt   150825

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20240124.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20240124_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20240124_pre.xml EX-101.PRE 11262
7 EXTRACTED XBRL INSTANCE DOCUMENT d687696d8k_htm.xml XML 3353
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 24567780
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)